Engagement Report for Clinical Commissioning Policies

Unique Reference Number	D04X09
Policy Title	Rituximab for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN), vasculitis of the peripheral nervous system and IgM paraprotein-associated demyelinating neuropathy (Adults)
Accountable Commissioner	Carolyn Young
Clinical Reference Group	Neurosciences
Which stakeholders were contacted to be involved in policy development?	Neurosciences CRG members Registered Neurosciences CRG stakeholders
Identify the relevant Royal College or Professional Society to the policy and indicate how they have been involved	Representatives of relevant Royal College or Professional Societies were contacted for Stakeholder Testing as part of the CRG
Which stakeholders have actually been involved?	All of the key stakeholders listed above were invited to comment.
Explain reason if there is any difference from previous question	Not applicable
Identify any particular stakeholder organisations that may be key to the policy development that you have approached that have yet to be engaged. Indicate why?	None

How have the stakeholders been involved? What engagement methods have been used?	The draft policy was circulated to the full membership of the CRG and registered stakeholders for one week for their views, both to establish whether any amendments to the policy are required, and to understand from their perspective what the key questions to ask at consultation might be. Three responses were received from CRG stakeholders, one from a Consultant Haematologist and two from Consultant Neurologists who have received payments from pharmaceutical companies. One response accepted that Rituximab should not be routinely commissioned for CIDP but felt that Rituximab should be available for severe refractory cases. The two responses from Consultant Neurologists requested that additional evidence be considered and that the decision for rituximab for IgM paraprotein-associated demyelinating neuropathy be reconsidered. Several respondents also asked for the British Peripheral Nerve Society and GAIN charity to be engaged as part of the process and also requested some minor clarifications to be made to the policy proposition.
What has happened or changed as a result of their input?	Stakeholders were invited to comment. The additional evidence proposed was reviewed and found to be outside the evidence review inclusion criteria. A few minor clarifications were made to the policy proposition. The British Peripheral Nerve Society and GAIN charity will be invited to comment as part of public consultation. This engagement report will form part of the consultation on the policy proposal. Stakeholders will be notified of consultation dates.
How are stakeholders being kept informed of progress with policy development as a result of their input?	This engagement report, along with the policy proposition, will be circulated as part of the public consultation. Stakeholders will be notified and invited to comment further.
What level of wider public consultation is recommended by the CRG for the NPOC Board to agree as a result of stakeholder involvement?	Public consultation for a period of 30 days as supported by stakeholders.